AUS
NZ
UK
CA
USA
IND
Highlights
- JHX and CSL remain notable names in the ASX 200 landscape
- Building materials and healthcare sectors take center stage
- Long-term growth trends continue to attract market interest
James Hardie Industries plc (JHX) and CSL Ltd (CSL) are two well-recognised companies within the ASX 200, each operating in very different industries but both drawing considerable investor attention.
James Hardie Industries is a global leader in building solutions, renowned for its fibre cement and gypsum products. The company’s products are widely used across residential and commercial construction, valued for their durability, resistance to fire, moisture, and termite damage, as well as low maintenance needs. With operations spanning North America, Europe, Australia, and New Zealand, JHX has established a strong international footprint supported by thousands of employees worldwide.
On the other hand, CSL operates in the healthcare sector, developing and delivering medicines and treatments that address serious medical conditions. Its operations are spread across three divisions — CSL Behring, CSL Seqirus, and CSL Vifor — covering plasma therapies, influenza vaccines, and treatments in iron deficiency and kidney care.
JHX (ASX:JHX) Share Price Context
JHX shares have seen some shifts in 2025, leading to discussions on how they compare against historical valuation metrics. One method of assessment is the price-to-sales ratio, which can provide an indication of how the market is valuing the company relative to its revenue. Historical comparisons show variations in this metric, influenced by both market sentiment and changes in sales figures over time.
For JHX, recent years have seen steady revenue growth, which could play a role in shaping its current market standing. However, it’s essential to view this in context, alongside broader industry trends and economic conditions impacting construction and housing markets globally.
CSL’s (ASX:CSL) Position in the Healthcare Market
CSL’s long-standing reputation for consistent dividend payouts has helped it remain a sought-after name among those seeking exposure to the healthcare sector. Its diversified business model and global reach allow it to adapt to changing healthcare demands.
The company’s divisions operate in specialised areas, with CSL Behring focusing on plasma therapies, CSL Seqirus on influenza vaccines, and CSL Vifor on iron and kidney health products. This diversification has allowed CSL to maintain a steady presence in the market, supported by global healthcare demand.
Frequently Asked Questions
- Are both JHX and CSL part of the ASX 200?
Yes, both companies are listed on the ASX and are part of the ASX 200 index, representing some of Australia’s largest publicly traded companies. - What sectors do JHX and CSL operate in?
JHX operates in the building materials sector, while CSL is a major player in the healthcare industry. - Why do investors monitor these companies closely?
Their strong market positions, international operations, and consistent performance histories make them significant in their respective industries, attracting ongoing market interest.
